oncogenes

oncogenes are genes that have the potential to cause cancer, as discovered by Harold Varmus and Michael Bishop at the University of California, San Francisco. They are normal genes that, when altered by mutation or amplification, can promote cell growth and proliferation, leading to the development of cancer, as seen in tumor suppressor genes such as TP53 and RB1. The study of oncogenes has been instrumental in understanding the molecular basis of cancer, with key contributions from researchers like James Allison and Tasuku Honjo at the University of Texas and Kyoto University. Oncogenes have been implicated in various types of cancer, including breast cancer, lung cancer, and colorectal cancer, which are often treated at institutions like the National Cancer Institute and the Memorial Sloan Kettering Cancer Center.

Introduction to Oncogenes

Oncogenes were first identified in the 1970s by Peter Duesberg and Peter Vogt at the University of California, Los Angeles and the University of Southern California, who discovered that certain retroviruses could cause cancer in animals. The src gene was one of the first oncogenes to be identified, and it has been extensively studied by researchers like Ray Erikson at the University of Colorado Boulder. Since then, many other oncogenes have been discovered, including HER2 and KRAS, which are often targeted by therapies developed at companies like Genentech and Amgen. The study of oncogenes has been facilitated by advances in molecular biology and genomics, with key contributions from institutions like the Broad Institute and the Wellcome Sanger Institute.

Mechanism of Oncogene Activation

Oncogenes can be activated by various mechanisms, including point mutations, chromosomal translocations, and gene amplification, as seen in Burkitt lymphoma and chronic myeloid leukemia. For example, the BCR-ABL fusion gene, which is characteristic of chronic myeloid leukemia, is formed by a chromosomal translocation between chromosome 9 and chromosome 22, and is often treated with imatinib developed at Novartis. The RAS oncogene, which is frequently mutated in lung cancer and colorectal cancer, can be activated by point mutations that affect its GTPase activity, and is being targeted by therapies developed at companies like AstraZeneca and Pfizer. The activation of oncogenes can lead to the development of cancer, as seen in tumor progression and metastasis, which are often studied at institutions like the National Institutes of Health and the Cancer Research UK.

Types of Oncogenes

There are several types of oncogenes, including growth factor receptors like EGFR and PDGFR, which are often targeted by therapies developed at companies like Roche and Merck KGaA. Other types of oncogenes include cytokine receptors like JAK2 and STAT3, which are involved in signal transduction pathways, and are being studied by researchers like Charles Sawyers at the Memorial Sloan Kettering Cancer Center. The MYC oncogene, which is a transcription factor, is often overexpressed in cancer, and is being targeted by therapies developed at institutions like the University of Pennsylvania and the Dana-Farber Cancer Institute. The PI3K oncogene, which is involved in cell survival and proliferation, is frequently mutated in cancer, and is being studied by researchers like Lewis Cantley at the Weill Cornell Medical College.

Role in Cancer Development

Oncogenes play a critical role in the development of cancer, as they can promote cell growth and proliferation, and inhibit apoptosis and cell cycle arrest, as seen in cancer stem cells and tumor microenvironment. The activation of oncogenes can lead to the development of cancer, as seen in tumor initiation and tumor progression, which are often studied at institutions like the Stanford University and the University of Chicago. For example, the KRAS oncogene is frequently mutated in lung cancer and colorectal cancer, and is being targeted by therapies developed at companies like Bristol-Myers Squibb and Eli Lilly and Company. The HER2 oncogene is overexpressed in breast cancer, and is being targeted by therapies developed at companies like Genentech and GlaxoSmithKline.

Oncogene Regulation and Signaling

Oncogenes are regulated by various mechanisms, including feedback inhibition and negative regulation by tumor suppressor genes like TP53 and RB1, which are often studied at institutions like the Harvard University and the University of California, Berkeley. The PI3K/AKT signaling pathway, which is involved in cell survival and proliferation, is frequently activated in cancer, and is being targeted by therapies developed at companies like Novartis and Pfizer. The RAS/RAF/MEK signaling pathway, which is involved in cell growth and proliferation, is often activated in cancer, and is being studied by researchers like Frank McCormick at the University of California, San Francisco. The regulation of oncogenes is critical for the development of cancer, as seen in cancer initiation and cancer progression, which are often studied at institutions like the Johns Hopkins University and the University of Oxford.

Therapeutic Targeting of Oncogenes

Oncogenes are attractive targets for cancer therapy, as they are often mutated or overexpressed in cancer, and are being targeted by therapies developed at companies like Roche and Merck KGaA. For example, the HER2 oncogene is targeted by trastuzumab and pertuzumab, which are used to treat breast cancer at institutions like the Memorial Sloan Kettering Cancer Center and the MD Anderson Cancer Center. The BRAF oncogene is targeted by vemurafenib and dabrafenib, which are used to treat melanoma at institutions like the University of California, Los Angeles and the Dana-Farber Cancer Institute. The KRAS oncogene is being targeted by therapies developed at companies like Amgen and AstraZeneca, and is being studied by researchers like Charles Swanton at the Francis Crick Institute. The therapeutic targeting of oncogenes has the potential to improve cancer treatment, as seen in precision medicine and personalized medicine, which are often developed at institutions like the National Cancer Institute and the Cancer Research UK. Category:Genetics